Structure Therapeutics Inc (GPCR) Stock Analysis
Verdict: AVOID
Severe technical momentum decay and zero insider buying obscure a $799.6M cash cushion backing oral GLP-1 clinical trials.
Investment score: 35/100
Analysis as of
Is Structure Therapeutics Inc stock worth reviewing? The TradeMates thesis
Structure Therapeutics trades near its 52-week low of $20.73 despite $799.6M in cash (~42 months runway), weighed down by clinical burn and heavy insider selling.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Structure Therapeutics Inc opportunities and risks
What speaks for GPCR
- Substantial Cash Runway of $799.6M
What speaks against GPCR
- Clinical Phase Binary Risk and Clinical Trial Setbacks
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GPCR | n/a | 0.0x | n/a | 0.0% | 0.0% | -18.4% |
| TRVI | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.2% |
| MAZE | n/a | 86.1x | n/a | 95.3% | -668.0% | -6.2% |
| ANIP | 15.0x | 1.7x | 6.4x | 65.2% | 10.8% | 9.6% |
| NUVB | n/a | 9.4x | n/a | 93.9% | -88.2% | -7.6% |
| PAHC | 15.8x | 1.0x | 9.7x | 33.7% | 6.6% | 0.6% |
| Peer median | n/a | 1.7x | n/a | 65.2% | 0.0% | -2.2% |
Frequently asked questions about Structure Therapeutics Inc (GPCR)
Is GPCR stock a good investment?
The TradeMates model rates Structure Therapeutics Inc as AVOID with an investment score of 35/100. Structure Therapeutics trades near its 52-week low of $20.73 despite $799.6M in cash (~42 months runway), weighed down by clinical burn and heavy insider selling. This is algorithmic model output, not personal investment advice.
Is GPCR stock a buy?
The TradeMates model verdict for GPCR is AVOID with an investment score of 35/100. Treat this as a model signal to review, not a personal buy recommendation.